Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: A preliminary study
Advances in Clinical and Experimental Medicine · 2022
DOI: 10.17219/acem/155373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2022. Verfasst von Piotr Łacina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, W…. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, MicroRNAs, Extracellular Vesicles. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Chronic graft-versus-host disease (cGvHD) is a complex disorder that typically manifests after allogeneic hematopoietic stem cell transplantation (HSCT). It is a major cause of non-relapse mortality, which makes finding biomarkers associated with its occurrence a priority. Recent studies increasingly indicate that microRNAs (miRNAs, short regulatory RNA molecules) can be used as biomarkers of various disorders. They can circulate in patients' bodies encapsulated within extracellular vesicles (EVs). OBJECTIVES: To identify miRNAs associated with the occurrence of cGvHD in EVs isolated from the plasma of patients after allogeneic HSCT. MATERIAL AND METHODS: We performed global miRNA expression profiling in a pilot cohort of 3 cGvHD cases and 4 non-cGvHD patients without disease symptoms 90 days after the transplantation (control group). RESULTS: The 2 groups were naturally clustered according to their miRNA profiles using unsupervised hierarchical clustering analysis. We identified 3 miRNAs that were differentially expressed in the cGvHD patients compared to the non-cGvHD patients. The levels of hsa-miR-630 and hsa-miR-374b-5p were lower in the cGvHD patients: 4.1-fold (p = 0.002) and 2.7-fold (p = 0.044), respectively. In contrast, the levels of hsa-miR-29c-3p were 5.8-fold higher (p = 0.004). CONCLUSIONS: Our results suggest that miRNA profiles from plasma EVs may act as markers of cGvHD onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom.
- Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
- Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Poland.
Zitieren
APA
Łacina, P., Crossland, R. E., Wielińska, J., Czyż, A., Szeremet, A., Ussowicz, M., Wróbel, T., Dickinson, A. M., & Bogunia-Kubik, K. (2022). Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: A preliminary study. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/155373
Vancouver
Łacina P, Crossland RE, Wielińska J, Czyż A, Szeremet A, Ussowicz M, et al. Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: A preliminary study. Advances in Clinical and Experimental Medicine. 2022. doi:10.17219/acem/155373
BibTeX
@article{acina2022,
author = {Łacina, Piotr and Crossland, Rachel E and Wielińska, Joanna and Czyż, Anna and Szeremet, Agnieszka and Ussowicz, Marek and Wróbel, Tomasz and Dickinson, Anne M and Bogunia-Kubik, Katarzyna},
title = {Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: A preliminary study},
journal = {Advances in Clinical and Experimental Medicine},
year = {2022},
doi = {10.17219/acem/155373}
}
EUVIMED